Recombinant Desmodus rotundus Salivary Plasminogen Activator Crosses the Blood–Brain Barrier Through a Low-Density Lipoprotein Receptor-Related Protein-Dependent Mechanism Without Exerting Neurotoxic Effects

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Stroke

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.STR.0000258100.04923.84PMID 17325305
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction of Tissue Plasminogen Activator-Induced Matrix Metalloproteinase-9 by Simvastatin in Astrocytes

  2006cited by this paper
• Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset

  2006cited by this paper
• LRP and alphavbeta3 mediate tPA activation of smooth muscle cells.

  2006cited by this paper
• LRP and αvβ3 mediate tPA activation of smooth muscle cells

  2006cited by this paper
• The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase

  2005cited by this paper
• Vampire Bat Salivary Plasminogen Activator (Desmoteplase) Inhibits Tissue-Type Plasminogen Activator-Induced Potentiation of Excitotoxic Injury

  2005cited by this paper
• Neuroprotective Effect of Darbepoetin Alfa, a Novel Recombinant Erythropoietic Protein, in Focal Cerebral Ischemia in Rats

  2005cited by this paper
• Oxygen Glucose Deprivation Switches the Transport of tPA Across the Blood–Brain Barrier From an LRP-Dependent to an Increased LRP-Independent Process

  2005cited by this paper
• Tissue-Type Plasminogen Activator Crosses the Intact Blood-Brain Barrier by Low-Density Lipoprotein Receptor–Related Protein-Mediated Transcytosis

  2005cited by this paper
• Arginine 260 of the Amino-terminal Domain of NR1 Subunit Is Critical for Tissue-type Plasminogen Activator-mediated Enhancement of N-Methyl-D-aspartate Receptor Signaling*

  2004cited by this paper
• tPA and proteolysis in the neurovascular unit.

  2004cited by this paper
• Altered NO Function Contributes to Impairment of uPA and tPA Cerebrovasodilation after Brain Injury

  2004cited by this paper
• Equivocal roles of tissue-type plasminogen activator in stroke-induced injury.

  2004cited by this paper
• The Neurotoxicity of Tissue Plasminogen Activator?

  2004cited by this paper
• In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone.

  2004cited by this paper
• Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

  2004cited by this paper
• Vampire Bat Salivary Plasminogen Activator (Desmoteplase): A Unique Fibrinolytic Enzyme That Does Not Promote Neurodegeneration

  2003cited by this paper
• Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator

  2003cited by this paper
• Intercommunications between brain capillary endothelial cells and glial cells increase the transcellular permeability of the blood–brain barrier during ischaemia

  2002cited by this paper
• LRP: a multifunctional scavenger and signaling receptor.

  2001cited by this paper
• Neuronal Death and Blood–Brain Barrier Breakdown after Excitotoxic Injury Are Independent Processes

  1999cited by this paper
• In vitro model for evaluating drug transport across the blood-brain barrier.

  1999cited by this paper
• Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice

  1998cited by this paper
• Nonlinear pharmacokinetics of tissue‐type plasminogen activator in three animal species: a comparison of mathematical models

  1998cited by this paper
• Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator.

  1997cited by this paper
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

  1995cited by this paper
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group

  1995cited by this paper
• Tissue plasminogen activator for acute ischemic stroke.

  1995cited by this paper
• Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator

  1995cited by this paper
• Structural Features Mediating Fibrin Selectivity of Vampire Bat Plasminogen Activators (*)

  1995cited by this paper
• Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator.

  1994cited by this paper
• Plasmhogen Activators from the Saliva of Desmodus rotundus (Common Vampire Bat): Unique Fibrin Specificity

  1992cited by this paper

• Fibrin Selective Alteplase with Improved Thrombolysis and Inhibition Resistance Engineered by Rational Design

  2026cites this paper
• Improving stroke outcomes in hyperglycemic mice by modulating tPA/NMDAR signaling to reduce inflammation and hemorrhages

  2024cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase

  2021cites this paper
• Structural Biology and Protein Engineering of Thrombolytics

  2019cites this paper
• Fibrinolytic Capacity of Desmoteplase Compared to Tissue Plasminogen Activator in Rabbit Eyes

  2019cites this paper
• Recombinant tissue plasminogen activator induces long‐term anxiety‐like behaviors via the ERK1/2‐GAD1‐GABA cascade in the hippocampus of a rat model

  2018cites this paper
• Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke

  2018cites this paper
• Blood-Brain Barrier Protection as a Therapeutic Strategy for Acute Ischemic Stroke

  2017cites this paper
• Comment optimiser l'utilisation du CPU

  2016cites this paper
• Tissue-type plasminogen activator controls neuronal death by raising surface dynamics of extrasynaptic NMDA receptors

  2016cites this paper
• The plasminogen activation system in neuroinflammation.

  2016cites this paper
• A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral Ischemia

  2016cites this paper
• Tissue plasminogen activator (tPA) attenuates propofol-induced apoptosis in developing hippocampal neurons

  2016cites this paper
• Understanding the Functions of Endogenous and Exogenous Tissue-Type Plasminogen Activator During Stroke

  2015cites this paper
• Impacts of tissue-type plasminogen activator (tPA) on neuronal survival

  2015cites this paper
• [Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].

  2015cites this paper
• Fisiopatologia dell’ischemia cerebrale

  2015cites this paper
• Recombinant Tissue-Type Plasminogen Activator Transiently Enhances Blood–Brain Barrier Permeability During Cerebral Ischemia through Vascular Endothelial Growth Factor-Mediated Endothelial Endocytosis in Mice

  2015cites this paper
• Physiopathologie de l’ischémie cérébrale

  2014cites this paper
• Факторы, влияющие на эффективность и безопасность системного тромболизиса у пациентов с ишемическим инсультом

  2014cites this paper
• t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions.

  2014cites this paper
• Molecular requirements for safer generation of thrombolytics by bioengineering the tissue‐type plasminogen activator A chain

  2013cites this paper
• The use of desmoteplase (bat saliva) in the treatment of ischaemia

  2013cites this paper
• Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke.

  2013cites this paper
• Studies into the interaction between the plasminogen activating system and the blood-brain barrier

  2013influential citation
• Vascular protection to increase the safety of tissue plasminogen activator for stroke.

  2012cites this paper
• Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology

  2012cites this paper
• La barrière hémato-encéphalique lors de l’ischémie cérébrale : une cible thérapeutique

  2012cites this paper
• t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes.

  2012cites this paper
• The Desmoteplase in Acute Ischemic Stroke (DIAS) Clinical Trial Program

  2012cites this paper
• Pathophysiology of the Neurovascular Unit: Disease Cause or Consequence?

  2012cites this paper
• plasmin-mediated activation of the Rho kinase pathway in astrocytes specific modulation of a human blood-brain barrier model involves - t-PA

  2012cites this paper
• [Dysfunction of the blood-brain barrier during ischaemia: a therapeutic concern].

  2012cites this paper
• Desmoteplase: discovery, insights and opportunities for ischaemic stroke

  2012influential citation
• Clinical investigation of desmoteplase in acute ischemic stroke: rationale and progress

  2011cites this paper
• Plasminogen activation-based thrombolysis for ischaemic stroke: the diversity of targets may demand new approaches.

  2011cites this paper
• Impact of Tissue Plasminogen Activator on the Neurovascular Unit: From Clinical Data to Experimental Evidence

  2011cites this paper
• HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator

  2011cites this paper
• Intra-arterial versus intra-venous thrombolysis within and after the first 3 hours of stroke onset

  2010cites this paper
• Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator.

  2010cites this paper
• Using Advanced MRI Techniques for Patient Selection Before Acute Stroke Therapy

  2010cites this paper
• Bat Plasminogen Activator: Desmoteplase – From Bat to Bench to Bedside of Stroke Victims

  2010cites this paper
• On the Regulation of the Serine Protease t-PA and its Inhibitor PAI-1 in the Brain

  2010cites this paper
• Comment l'utilisation ?

  2009cites this paper
• Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier.

  2009cites this paper
• PPACK-Desmodus rotundus salivary plasminogen activator (cDSPAα1) prevents the passage of tissuetype plasminogen activator (rt-PA) across the blood-brain barrier and neurotoxicity

  2009cites this paper
• [Cerebral ischemia (2), How to neutralize the neurotoxic effects of tPA].

  2009cites this paper
• Implication de la barrière hématoencéphalique dans la physiopathologie des maladies neurologiques : Partie II

  2009cites this paper
• [Implication of the blood-brain barrier in neurological diseases: part II].

  2009cites this paper
• The blood-brain barrier in brain homeostasis and neurological diseases.

  2009cites this paper
• Desmoteplase

  2009cites this paper
• Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic.

  2009cites this paper
• Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly

  2008cites this paper
• Recent advances in intra-arterial thrombolysis

  2008cites this paper
• Marrying Activase with Gleevec

  2008cites this paper
• Toward Safer Thrombolytic Agents in Stroke: Molecular Requirements for NMDA Receptor-Mediated Neurotoxicity

  2008cites this paper
• Magnetic Resonance Imaging in the Evaluation of Acute Stroke

  2008cites this paper
• Novel Thrombolytic Drugs

  2008cites this paper
• Management of delayed edema formation after fibrinolytic therapy for intracerebral hematomas: preliminary experimental data.

  2008cites this paper
• Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.

  2008cites this paper
• Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory

  2007cites this paper
• Neuroprotection and stroke: time for a compromise

  2007cites this paper
• Modelling of the blood–brain barrier in drug discovery and development

  2007cites this paper